PR Newswire BiotechnologyCodex · 实盘不做把握 9/10
北京时间·🕒 发布 18:00:00时区推断·⟳ 抓取 18:00:28·⚡ 决策 08-06 18:03:37 +3m09s·82.5 天前
海默耐吉发布 2027 财年第一财季财报已上线公告及电话会安排
该公告仅说明 FY2027 第一财季财报已在官网发布并预告电话会时间，未披露营收、利润或指引等关键财务数据。
📄 原文PR Newswire Biotechnology↗ 原文
Financial release and supplemental presentation accessible online BOSTON, Aug. 6, 2026 /PRNewswire/ -- Haemonetics Corp…
不做 Haemonetics Corporation (HAE.US)（HAE.US）
当前为财报披露预告，未给出营收/利润/指引等可核算催化数据，无法形成明确方向与可交易边界，先不建仓，待正式财报公布后再评估。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-06 · 扩散 low · price-in 风险 low ↗
关键理由
- 该公告仅说明 FY2027 第一财季财报已在官网发布并预告电话会时间，未披露营收、利润或指引等关键财务数据。
- 当前事件缺少新增业绩口径、增速和预期差信息，无法判定是否有可交易的正向或负向短线催化。
- 由于无法核实具体财报指标与市场预期偏差，且未出现明确利空或利多事实，当前不满足“方向确定+可执行”条件。
主要风险
- 若后续财报数字在正式披露时不及预期，可能引发二次下跌；但本条当前仅为披露预告，尚不能用来提前建仓。
原文全文
展开原文 · 1,916 字
Financial release and supplemental presentation accessible online
BOSTON, Aug. 6, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its first quarter fiscal year 2027, which ended June 27, 2026, are available on the Company's Investor Relations website at www.haemonetics.com.
The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on August 6, 2026.
Conference Call and Webcast Information:
A replay of the conference call and webcast will be available beginning at 11:00 a.m. ET on August 6, 2026 and will remain accessible for one year via the webcast link above.
Earnings Materials:
Haemonetics has also posted the following materials on its Investor Relations website, which will be referenced during the conference call and webcast:
ABOUT HAEMONETICS
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our Apheresis business features proprietary technologies designed to enhance safety, yield, donor satisfaction and operational efficiency for plasma and blood collectors around the world. Our MedSurg business offers Blood Management Technologies to help inform treatment decisions and optimize the management of blood products, and Interventional Technologies, including advanced vascular closure systems and sensor-guided technologies, designed to drive procedural effectiveness and elevate the patient experience. To learn more about Haemonetics, visit www.haemonetics.com.
Investor Contacts:
Olga Guyette, Vice President-Investor Relations & Treasury
(781) 356-9763
[email protected]
David Trenk, Sr. Manager-Investor Relations
(203) 733-4987
[email protected]
Media Contact:
Josh Gitelson, Sr. Director-Global Communications
(781) 356-9776
[email protected]
SOURCE Haemonetics Corporation
BOSTON, Aug. 6, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its first quarter fiscal year 2027, which ended June 27, 2026, are available on the Company's Investor Relations website at www.haemonetics.com.
The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on August 6, 2026.
Conference Call and Webcast Information:
A replay of the conference call and webcast will be available beginning at 11:00 a.m. ET on August 6, 2026 and will remain accessible for one year via the webcast link above.
Earnings Materials:
Haemonetics has also posted the following materials on its Investor Relations website, which will be referenced during the conference call and webcast:
ABOUT HAEMONETICS
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our Apheresis business features proprietary technologies designed to enhance safety, yield, donor satisfaction and operational efficiency for plasma and blood collectors around the world. Our MedSurg business offers Blood Management Technologies to help inform treatment decisions and optimize the management of blood products, and Interventional Technologies, including advanced vascular closure systems and sensor-guided technologies, designed to drive procedural effectiveness and elevate the patient experience. To learn more about Haemonetics, visit www.haemonetics.com.
Investor Contacts:
Olga Guyette, Vice President-Investor Relations & Treasury
(781) 356-9763
[email protected]
David Trenk, Sr. Manager-Investor Relations
(203) 733-4987
[email protected]
Media Contact:
Josh Gitelson, Sr. Director-Global Communications
(781) 356-9776
[email protected]
SOURCE Haemonetics Corporation
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。